Potentiating effects of RAD001 (Everolimus) on vincristine therapy in childhood acute lymphoblastic leukemia

Blood

Volumn 113, Issue 14, 2009, Pages 3297-3306

  Crazzolara, Roman ^a   Cisterne, Adam ^a   Thien, Marilyn ^a   Hewson, John ^a   Baraz, Rana ^a   Bradstock, Kenneth F ^b   Bendall, Linda J ^a,c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

^c WESTMEAD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; EVEROLIMUS; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PLACEBO; RETINOBLASTOMA PROTEIN; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; AUTOPHAGY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CELL CYCLE ARREST; CELL ULTRASTRUCTURE; CHILD; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN DEPHOSPHORYLATION; SCHOOL CHILD; SCID MOUSE; SINGLE DRUG DOSE; STRUCTURE ANALYSIS;

EID: 65349114832     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-02-137752     Document Type: Article

References (49)

1. Pui C, Relling M, Campana D, Evans W. Childhood acute lymphoblastic leukemia. Rev Clin Exp Hematol. 2002;6:161-180.
2. Einsiedel H, von Stackelberg A, Hartmann R, et al. Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Munster Group 87. J Clin Oncol. 2005;23:7942-7950.
3. Dow L, Martin P, Moohr J, et al. Evidence for clonal development of childhood acute lymphoblastic leukemia. Blood. 1985;66:902-907.
4. Bertrand F, Spengemen J, Shelton J, McCubrey J. Inhibition of PI3K, mTOR and MEK signaling pathways promotes rapid apoptosis in B-lineage ALL in the presence of stromal cell support. Leukemia. 2005;19:98-102.
5. Wang L, Fortney J, Gibson L. Stromal cell protection of B-lineage acute lymphoblastic leukemic cells during chemotherapy requires active Akt. Leuk Res. 2004;28:733-742.
6. Juarez J, Baraz R, Gaundar S, Bradstock K, Bendall L. Interaction of interleukin-7 and interleukin-3 with the CXCL-12-induced proliferation of B cell progenitor acute lymphoblastic leukemia. Haematologica. 2007;92:450-459.
7. Avellino R, Romano S, Parasole R, et al. Rapa- mycin stimulates apoptosis of childhood acute lymphoblastic leukemia cells. Blood. 2005;106:1400-1406.
8. Mabuchi S, Altomare D, Cheung M, et al. RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Clin Cancer Res. 2007;13:4261-4270.
9. Peponi E, Drakos E, Reyes G, Leventaki V, Rassidakis G, Medeiros L. Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma. Am J Pathol. 2006;169:2171-2180.
10. Teachey D, Obzut D, Cooperman J, et al. The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL. Blood. 2006;107:1149-1155.
11. Yee K, Zeng Z, Konopleva M, et al. Phase I/II study of the mammalian target of rapamycin inhibitor Everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res. 2006;12:5165-5173.
12. Zeng Z, Sarbassov dos D, Samudio I, et al. Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood. 2007;109:3509-3512.
13. Dann S, Thomas G. The amino acid sensitive TOR pathway from yeast to mammals. FEBS Lett. 2006;580:2821-2829.
14. Thomas G. mTOR and cancer: reason for dancing at the crossroads? Curr Opin Genet Dev. 2006;16:78-84
15. Vignot S, Faivre S, Aguirre D, Raymond E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol. 2005;16:525-537.
16. Yu K, Toral-Barza L, Discafani C, et al. mTOR, a novel target in breast cancer: the effect of CCI- 779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer. 2001;8:249-258.
17. Khariwala S, Kjaergaard J, Lorenz R, Van Lente F, Shu S, Strome M. Everolimus (RAD) inhibits in vivo growth of murine squamous cell carcinoma (SCC VII). Laryngoscope. 2006;116:814-820.
18. Ito D, Fujimoto K, Mori T, et al. In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer. Int J Cancer. 2006;118:2337-2343.
19. Grunwald V, DeGraffenried L, Russel D, Friedrichs W, Ray R, Hidalgo M. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res. 2002;62:6141-6145.
20. Goudar R, Shi Q, Hjelmeland M, et al. Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblas- toma tumor growth inhibition. Mol Cancer Ther. 2005;4:101-112.
21. Pui C, Evans W. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354:166-178.
22. Bendall LJ, Kortlepel K, Gottlieb DJ. Human acute myeloid leukemia cells bind to bone marrow stroma via a combination of beta 1 and beta 2 integrin mechanisms. Blood. 1993;82:3125-3132.
23. Juarez J, Dela Pena A, Baraz R, et al. CXCR4 antagonists mobilize childhood acute lymphoblastic leukemia cells into the peripheral blood and inhibit engraftment. Leukemia. 2007;21:1249-1257.
24. Bendall L, Baraz R, Juarez J, Shen W, Bradstock K. Defective p38 mitogen-activated protein kinase signaling impairs chemotaxic but not prolif- erative responses to stromal-derived factor-1alpha in acute lymphoblastic leukemia. Cancer Res. 2005;65:3290-3298.
25. Khan N, Bradstock K, Bendall L. Activation of Wnt/beta-catenin pathway mediates growth and survival in B-cell progenitor acute lymphoblastic leukaemia. Br J Haematol. 2007;138:338-348.
26. Steinherz P, Gaynon P, Breneman J, et al. Cytoreduction and prognosis in acute lymphoblastic leukemia-the importance of early marrow response: report from the Childrens Cancer Group. J Clin Oncol. 1996;14:389-398.
27. Aguirre D, Boya P, Bellet D, et al. Bcl-2 and CCND1/CDK4 expression levels predict the cellular effects of mTOR inhibitors in human ovarian carcinoma. Apoptosis. 2004;9:797-805.
28. Cao Y, Klionsky D. Physiological functions of Atg6/Beclin 1: a unique autophagy-related protein. Cell Res. 2007;17:839-849.
29. Schrappe M, Camitta B, Pui C, et al. Long-term results of large prospective trials in childhood acute lymphoblastic leukemia. Leukemia. 2000;14:2193-2194.
30. Mabuchi S, Altomare D, Connolly D, et al. RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer. Cancer Res. 2007;67:2408-2413.
31. Kahan B, Wong R, Carter C, et al. A phase I study of a 4-week course of SDZ-RAD (RAD) quiescent cyclosporine-prednisone-treated renal transplant recipients. Transplantation. 1999;68:1100-1106.
32. Kovarik J, NoeA, BerthierS, et al. Clinical development of an everolimus pediatric formulation: relative bioavailability, food effect, and steady- state pharmacokinetics. J Clin Pharmacol. 2003;43:141-147.
33. Laplanche R, Meno-Tetang G, Kawai R. Physiologically based pharmacokinetic (PBPK) modeling of everolimus (RAD001) in rats involving nonlinear tissue uptake. J Pharmacokinet Pharmacodyn. 2007;34:373-400.
34. Cao C, Subhawong T, Albert J, et al. Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells. Cancer Res. 2006;66:10040-10047.
35. Borgmann A, Baldy C, von Stackelberg A, et al. Childhood ALL blasts retain phenotypic and genotypic characteristics upon long-term serial passage in NOD/SCID mice. Pediatr Hematol Oncol. 2000;17:635-650.
36. Liem N, Papa R, Milross C, et al. Characterization of childhood acute lymphoblastic leukemia xenograft models for the pre-clinical evaluation of new therapies. Blood. 2004;103:3905-3914.
37. Teachey D, Sheen C, Hall J, et al. mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia. Blood. 2008;112:2020-2023.
38. Roman-Gomez J, Jimenez-Velasco A, Castillejo J, et al. Promoter hypermethylation of cancer related genes: a strong independent prognostic factor in acute lymphoblastic leukemia. Blood. 2004;104:2492-2498.
39. Zhou M, Gu L, Findley H, Jiang R, Woods W. PTEN reverses MDM2-mediated chemotherapy resistance by interacting with p53 in acute lym- phoblastic leukemia cells. Cancer Res. 2003;63:6357-6362.
40. Wendel H, MalinaA, ZhaoZ, et al. Determinants of sensitivity and resistance to rapamycin-chemotherapy drug combinations in vivo. Cancer Res. 2006;66:7639-7646.
41. Sun S, Rosenberg L, Wang X, et al. Activation of Akt and eIF4E survival pathways by rapamycinmediated mammalian target of rapamycin inhibition. Cancer Res. 2005;65:7052-7058.
42. Grossel M, Hinds P. From cell cycle to differentiation: an expanding role for cdk6. Cell Cycle. 2006;5:266-270.
43. Gao N, Zhang Z, Jiang B, Shi X. Role of PI3K/ AKT/mTOR signaling in the cell cycle progression of human prostate cancer. Biochem Biophys Res Commun. 2003;310:1124-1132.
44. Gao N, Flynn D, Zhang Z, et al. G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells. Am J Physiol Cell Physiol. 2004;287:C281-C291.
45. Brown V, Fang J, Alcorn K, et al. Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling. Proc Natl Acad Sci USA. 2003; 100:15113-15118.
46. Gozuacik D, Kimchi A. Autophagy as a cell death and tumor suppressor mechanism. Oncogene. 2004;23:2891-2906.
47. Wei G, Twomey D, Lamb J, et al. Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell. 2006;10:331-342.
48. Gomez-Santos C, Ferrer I, Santidrian A, Barrachina M, Gil J, Ambrosio S. Dopamine induces autophagic cell death and alpha-synuclein increase in human neuroblastoma SH-SY5Y cells. J Neurosci Res. 2003;73:341-350.
49. Yu L, Wan F, Dutta S, et al. Autophagic programmed cell death by selective catalase degradation. Proc Natl Acad Sci U S A. 2006;103:4952- 4957.